sph3127
Small moleculeexperimental
Clinical trial activity
10 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT03128138)
Timeline
Indications
Mechanism of action
- ReninINHIBITOR
REN inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sph3127
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05770609 | Phase 2 | Jun 19, 2023 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT05593575 | Phase 2 | Dec 20, 2022 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT05593562 | Phase 1/Phase 2 (Phase 2) | Oct 16, 2022 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT05359055 | Phase 1/Phase 2 (Phase 2) | Dec 13, 2021 | Shanghai Pharmaceuticals Holding Co., Ltd, Sichuan University |
| NCT05019742 | Phase 2 | Sep 30, 2021 | Government of China |
| NCT05359068 | Phase 3 | Jun 10, 2021 | Capital Medical University, Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT03756103 | Phase 2 | Dec 20, 2018 | Capital Medical University, R&G Pharma Studies Co.,Ltd., Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT03255993 | Phase 1 | Oct 23, 2017 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT03249753 | Phase 1 | Sep 23, 2017 | Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT03128138 | Phase 1 | Dec 1, 2016 | Shanghai Pharmaceuticals Holding Co., Ltd |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Pharmaceuticals Holding Co., Ltd | For profit | 9 | 9 | 3 | 2016 |
| Capital Medical University | Academic/Hospital | 2 | 0 | 2 | 2018 |
| Government of China | Government | 1 | 1 | 1 | 2021 |
| R&G Pharma Studies Co.,Ltd. | For profit | 1 | 0 | 1 | 2018 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1